Medication Description: Menopausal Gonadotropin (Gonadotropinum menopausticum)
Gonadotropin menopausal (Gonadotropinum menopausticum).
Synonym: Gonadotropinum menopausalis.
Powder gray with a brownish tinge. Soluble in water. Activity is determined biologically (according to its ability to stimulate ovarian growth in immature female rats on the background of introducing chorionic gonadotropin); 1 mg of the drug contains at least 10 U.
For medical use, ganadotropin menopausal for injection (Gonadotropinum menopausticum pro injectionibus) is a lyophilized sterile powder that is ex mempore dissolved in sterile isotonic (0.9%) sodium chloride solution. One bottle contains 75 U.
The drug is used for infertility in women with ovarian hypofunction and anovulatory cycles (primary or secondary amenorrhea of central origin, hypomenstrual syndrome). In Skien syndrome, as well as in men with infertility of endocrine genesis (hypogonadotropic hypogonadism, eunuchoidism).
Gonadotropin is administered menopausal intramuscularly.
In the treatment of infertility in women, 75 or 150 IU are administered per day (in 1 or 2 ml of isotonic sodium chloride solution) for 10 days or longer until signs of complete follicle appear. To determine the optimal dose of the drug, it is recommended to determine the estrogen content in the blood and urine daily during the treatment process. If this is not possible, the functional state of the ovaries is judged by tests of functional diagnostics (a pronounced symptom of the pupil, etc.). 24-48 hours after the end of the injections of the drug, patients are prescribed human chorionic gonadotropin, 1,500–3,000 U per day intramuscularly for 3 days.
For male infertility, menopausal gonadotropin is prescribed in 75 U in combination with chorionic gonadotropin in 1000-2000 U.
Both drugs are administered intramuscularly every other day for 90-120 days.
Treatment must be carried out under close medical supervision. With over-stimulation of the ovaries, an increase in their size and pain in the pelvic region, an increase in estrogen excretion with urine are possible. When signs of ovarian hyperstimulation appear, the administration of drugs is stopped.
Product form: 75 U in bottles with a capacity of 5 ml, sealed with rubber stoppers and run-in with aluminum caps in a package of 5 bottles and 5 ampoules (1 ml) of isotonic sodium chloride solution.
Storage: List B. In a dry, dark place at a temperature not higher than + 20 C.